User login
Key clinical point: Enzalutamide was associated with worsening of self-reported fatigue, cognitive function, and physical function, but not overall health and quality of life (OHQL) in newly diagnosed patients with metastatic hormone-sensitive prostate cancer (HSPC).
Major finding: Conventional nonsteroidal antiandrogen vs enzalutamide was associated with less worsening of fatigue (mean difference [MD], 5.2; P < .001), cognitive function (MD, 4.0; P < .001), and physical function (MD, 2.6; P < .001), but not OHQL (MD, 1.2; P = .1).
Study details: An open-label, international, randomized, phase 3, cooperative group ENZAMET trial of newly diagnosed patients with metastatic prostate cancer who were randomly assigned to enzalutamide or a conventional nonsteroidal antiandrogen.
Disclosures: This study was funded by Astellas. The authors received speakers/advisory/consulting fees, honoraria, research funding, royalties, and travel/accommodation expenses; were employed by; held stocks/other ownership interests; and had leadership roles outside this work.
Source: Stockler MR et al. J Clin Oncol. 2021 Dec 20. doi: 10.1200/JCO.21.00941.
Key clinical point: Enzalutamide was associated with worsening of self-reported fatigue, cognitive function, and physical function, but not overall health and quality of life (OHQL) in newly diagnosed patients with metastatic hormone-sensitive prostate cancer (HSPC).
Major finding: Conventional nonsteroidal antiandrogen vs enzalutamide was associated with less worsening of fatigue (mean difference [MD], 5.2; P < .001), cognitive function (MD, 4.0; P < .001), and physical function (MD, 2.6; P < .001), but not OHQL (MD, 1.2; P = .1).
Study details: An open-label, international, randomized, phase 3, cooperative group ENZAMET trial of newly diagnosed patients with metastatic prostate cancer who were randomly assigned to enzalutamide or a conventional nonsteroidal antiandrogen.
Disclosures: This study was funded by Astellas. The authors received speakers/advisory/consulting fees, honoraria, research funding, royalties, and travel/accommodation expenses; were employed by; held stocks/other ownership interests; and had leadership roles outside this work.
Source: Stockler MR et al. J Clin Oncol. 2021 Dec 20. doi: 10.1200/JCO.21.00941.
Key clinical point: Enzalutamide was associated with worsening of self-reported fatigue, cognitive function, and physical function, but not overall health and quality of life (OHQL) in newly diagnosed patients with metastatic hormone-sensitive prostate cancer (HSPC).
Major finding: Conventional nonsteroidal antiandrogen vs enzalutamide was associated with less worsening of fatigue (mean difference [MD], 5.2; P < .001), cognitive function (MD, 4.0; P < .001), and physical function (MD, 2.6; P < .001), but not OHQL (MD, 1.2; P = .1).
Study details: An open-label, international, randomized, phase 3, cooperative group ENZAMET trial of newly diagnosed patients with metastatic prostate cancer who were randomly assigned to enzalutamide or a conventional nonsteroidal antiandrogen.
Disclosures: This study was funded by Astellas. The authors received speakers/advisory/consulting fees, honoraria, research funding, royalties, and travel/accommodation expenses; were employed by; held stocks/other ownership interests; and had leadership roles outside this work.
Source: Stockler MR et al. J Clin Oncol. 2021 Dec 20. doi: 10.1200/JCO.21.00941.